纳武利尤单抗二线治疗复发小细胞肺癌:CheckMate 331
CheckMate 331 是一项随机、开放标签、III 期试验,比较纳武利尤单抗与标准化疗在铂类一线治疗后复发小细胞肺癌中的疗效。共随机 284 例至纳武利尤单抗组、285 例至化疗组,主要终点总生存期(OS)无显著改善(中位 OS 7.5 对 8.4 个月;HR 0.86;95%CI 0.72-1.04;P=0.11)。探索性分析提示基线乳酸脱氢酶≤正常上限及无基线肝转移者可能从纳武利尤单抗获益。
要点
- 纳武利尤单抗二线治疗复发 SCLC 未显著改善 OS,中位 OS 7.5 对 8.4 个月(HR 0.86;P=0.11)。
- PD-L1 联合阳性评分≥1% 与<1% 患者 OS 相似,未见 PD-L1 预测价值。
- 纳武利尤单抗组 3/4 级治疗相关不良事件发生率 13.8%,低于化疗组 73.2%。
核心结论
- 纳武利尤单抗对比标准化疗未改善复发小细胞肺癌患者的总生存期,未发现新的安全性信号。
研究设计与样本
- CheckMate 331 为随机、开放标签、III 期试验,纳入一线铂类化疗后复发的小细胞肺癌患者。
- 患者按 1:1 随机接受纳武利尤单抗 240 mg 每 2 周或化疗(拓扑替康或氨柔比星),直至进展或不可接受毒性。
- 共 284 例随机至纳武利尤单抗组,285 例至化疗组,主要终点为总生存期(OS)。
主要发现
- 纳武利尤单抗组与化疗组中位 OS 分别为 7.5 个月与 8.4 个月(HR 0.86;95%CI 0.72-1.04;P=0.11),无显著改善。
- 基线乳酸脱氢酶≤正常上限及无基线肝转移的患者中,纳武利尤单抗似有生存获益。
- PD-L1 联合阳性评分≥1% 与<1% 患者中,纳武利尤单抗与化疗的 OS 相似。
- 中位无进展生存期分别为 1.4 个月与 3.8 个月(HR 1.41;95%CI 1.18-1.69)。
- 客观缓解率分别为 13.7% 与 16.5%(比值比 0.80;95%CI 0.50-1.27);中位缓解持续时间分别为 8.3 个月与 4.5 个月。
关键数值与推荐
- 纳武利尤单抗组中位 OS 7.5 个月,化疗组 8.4 个月,HR 0.86(95%CI 0.72-1.04;P=0.11)。
- 纳武利尤单抗组中位 PFS 1.4 个月,化疗组 3.8 个月,HR 1.41(95%CI 1.18-1.69)。
- 纳武利尤单抗组 ORR 13.7%,化疗组 16.5%,比值比 0.80(95%CI 0.50-1.27)。
- 纳武利尤单抗组中位 DOR 8.3 个月,化疗组 4.5 个月。
- 纳武利尤单抗组 3/4 级治疗相关不良事件发生率 13.8%,化疗组 73.2%。
临床怎么用
- 复发小细胞肺癌二线治疗中,纳武利尤单抗未优于标准化疗,不应作为常规首选。
- 探索性亚组(基线 LDH≤正常上限、无肝转移)可能从纳武利尤单抗获益,需进一步验证。
- PD-L1 联合阳性评分不能用于筛选纳武利尤单抗获益人群。
局限性
- 探索性亚组分析结果需前瞻性验证,不能作为临床决策依据。
- 研究为开放标签设计,可能影响部分终点评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase I/II data show activity of nivolumab in previously treated SCLC. PATIENTS AND METHODS: CheckMate 331 is a randomized, open-label, phase III trial of nivolumab versus standard chemotherapy in relapsed SCLC. Patients with relapse after first-line, platinum-based chemotherapy were randomized 1 : 1 to nivolumab 240 mg every 2 weeks or chemotherapy (topotecan or amrubicin) until progression or unacceptable toxicity. Primary endpoint was overall survival (OS). RESULTS: Overall, 284 patients were randomized to nivolumab and 285 to chemotherapy. Minimum follow-up was 15.8 months. No significant improvement in OS was seen with nivolumab versus chemotherapy [median OS, 7.5 versus 8.4 months; hazard ratio (HR), 0.86; 95% confidence interval (CI), 0.72-1.04; P = 0.11]. A survival benefit with nivolumab was suggested in patients with baseline lactate dehydrogenase ≤ upper limit of normal and in those without baseline liver metastases. OS (nivolumab versus chemotherapy) was similar in patients with programmed death-ligand 1 combined positive score ≥1% versus <1%. Median progression-free survival was 1.4 versus 3.8 months (HR, 1.41; 95% CI, 1.18-1.69). Objective response rate was 13.7% versus 16.5% (odds ratio, 0.80; 95% CI, 0.50-1.27); median duration of response was 8.3 versus 4.5 months. Rates of grade 3 or 4 treatment-related adverse events were 13.8% versus 73.2%. CONCLUSION: Nivolumab did not improve survival versus chemotherapy in relapsed SCLC. No new safety signals were seen. In exploratory analyses, select baseline characteristics were associated with improved OS for nivolumab.
引用
- Spigel DR, Vicente D, Ciuleanu TE, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆. Ann Oncol. 2021. PMID: 33539946. doi:10.1016/j.annonc.2021.01.071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。